{"filing":{"accession_number":"0001628280-26-049466","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-23","primary_document":"jazz-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026049466/jazz-20260723.htm"},"events":[{"id":20270,"run_id":18248,"accession_number":"0001628280-26-049466","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Jazz Pharmaceuticals' 2026 Annual General Meeting held on July 23, 2026. The filing reports voting outcomes on six proposals including director elections (Proposal 1), auditor ratification (Proposal 2), executive compensation approval (Proposal 3), and board authority matters (Proposals 4-5), with detailed vote tallies for each. This is a quintessential Item 5.07 shareholder vote results disclosure that is material to investors as it reflects shareholder approval of key governance and compensation matters.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19585,"accession_number":"0001628280-26-049466","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Jazz Pharmaceuticals' 2026 Annual General Meeting held on July 23, 2026. The filing reports voting outcomes on six proposals including director elections (Proposal 1), auditor ratification (Proposal 2), executive compensation approval (Proposal 3), and board authority matters (Proposals 4-5), with detailed vote tallies for each. This is a quintessential Item 5.07 shareholder vote results disclosure that is material to investors as it reflects shareholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T10:17:36.388270+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19585,"accession_number":"0001628280-26-049466","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Jazz Pharmaceuticals' 2026 Annual General Meeting held on July 23, 2026. The filing reports voting outcomes on six proposals including director elections (Proposal 1), auditor ratification (Proposal 2), executive compensation approval (Proposal 3), and board authority matters (Proposals 4-5), with detailed vote tallies for each. This is a quintessential Item 5.07 shareholder vote results disclosure that is material to investors as it reflects shareholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T10:17:36.388270+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-07-24"}]}